Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab.

Ysoline BeigneuxCeline LouapreKevin BihanThomas RouxRaphael de PazCatherine LubetzkiElisabeth Maillart

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)

Given the risk of recurrence of symptomatic agranulocytosis and the availability of other treatments, a therapeutic switch may be discussed after the first episode of LON.

Keyphrases

late onset
early onset
free survival